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Résumé 
       La stimulation du récepteur de la rénine/prorénine  [(P) RR], un membre récemment découvert 
du système rénine-angiotensine (SRA), augmente l'activité du SRA et des voies de signalisation 
angiotensine II-indépendante. Pour étudier l'impact potentiel du (P)RR dans le développement de 
l`obésité, nous avons émis l'hypothèse que les souris déficientes en (P)RR uniquement dans le 
tissus adipeux (KO) auront une diminution du poids corporel en ciblant le métabolisme du tissu 
adipeux, l'activité locomoteur et/ou la prise alimentaire. Ainsi, des souris KO ont été générées en 
utilisant la technologie Cre/Lox. Le gain de poids et la prise alimentaire ont été évalués 
hebdomadairement dans les mâles et femelles KO et de type sauvage (WT) pendant 4 semaines 
alors qu’ils étaient maintenu sur une diète normal. De plus, un groupe de femelles a été placé pour 
6 semaines sur une diète riche en gras et en glucides (HF/HC). La composition corporelle et 
l'activité ambulatoire ont été évaluées par l’EchoMRI et à l’aide de cages Physioscan, 
respectivement. Les tissus adipeux ont été prélevés et pesés. De plus, les gras péri-gonadaux ont 
été utilisés pour le microarray. Finalement, le niveaux d'expression d'ARNm du (P)RR ont été 
évalués.  
        Comme le gène du (P)RR est situé sur le chromosome X, les mâles étaient des KOs complets 
et les femelles étaient des KOs partielles. Les souris KO avaient un poids corporel 
significativement plus petit par rapport à WT, les différences étant plus prononcées chez les mâles. 
De plus, les femelles KOs étaient résistantes à l'obésité lorsqu'elles ont été placées sur la diète 
HF/HC et donc elles avaient significativement moins de masse grasse par rapport aux WTs. 
L’analyse histologique des gras péri-gonadaux des KOs nous ont dévoilés qu’il avait une réduction 
du nombre d'adipocytes mais de plus grande taille. Bien qu'il n'y ait eu aucun changement dans la 
consommation alimentaire, une augmentation de près de 3 fois de l'activité ambulatoire a été 
détectée chez les mâles. De plus, nous avons observé que leurs tibias étaient de longueur réduite ce 
qui suggère fortement l'affection de leur développement. Les gras péri-gonadaux des souris KO 
avaient une expression réduite de l`ABLIM2 (Actin binding LIM protein family, member 2) qui 
est associé avec le diabète de type II chez l'humain. Ainsi, les données recueillies suggèrent 
fortement que le (P)RR est impliquée dans la régulation du poids corporelle. 
Mots-clés: Le récepteur de la rénine/prorénine, tissue adipeux, obésité, le système rénine-
angiotensine, Souris KO  
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Abstract 
      Stimulation of the (pro)renin receptor [(P)RR], a recently discovered member of the renin-
angiotensin system (RAS), increases the activity of the RAS and stimulates angiotensin II-
independent signaling pathways. To investigate the possible impact of the (P)RR on obesity 
development, we hypothesized that mice deficient in the (P)RR specifically in their adipose tissue 
(KO) would have a decrease in body weight by targeting adipose tissue metabolism, locomotor 
activity and/or food intake. As such, KO mice were generated using the Cre/Lox technology. 
Weekly weight gain and food intake were assessed in both male and female KO and wild-type 
(WT) littermates for 4 weeks on a normal diet. A group of females were also placed for an 
additional 6 weeks on a high-fat/high-carbohydrate diet (HF/HC). Body composition and physical 
activity were evaluated using EchoMRI and Physioscan cages, respectively. Adipose tissues were 
collected and weighed at sacrifice. Moreover, perigonadal fat was used for Gene assay and 
histological analysis. (P)RR mRNA expression levels were evaluated using real-time PCR. 
Different circulating metabolites and proteinuria were measured by ELISA kits.  
        As the (P)RR gene is located on the X chromosome, males were complete KOs and females 
were partial KOs. KO body weights were significantly lower compared to WTs, the differences 
being more pronounced in males. Female KOs were resistant to obesity development when placed 
on a HF/HC diet and as such, had significantly smaller fat mass as well as lower circulating leptin 
levels compared to WTs. All KO perigonadal fat had a reduced number of adipocytes but of bigger 
size. Although there were no changes in food intake, an almost 3-fold increase in activity was 
detected in males. Moreover, they presented with shorter tibial length which strongly suggests that 
they may have developmental issues. Gonadal fat of KO mice showed a reduced expression of 
ABLIM2 gene (Actin binding LIM protein family, member 2) which is associated with type II 
diabetes in humans. Conversely, no obvious changes in glycemia were detected while tendencies 
for lower proteinuria could be observed.  
      The data collected thus strongly suggests that the (P)RR is implicated in body weight 
regulation.  
Keywords: (Pro)renin receptor, Adipose tissue, Renin-Angiotensin system, Obesity, Knocked out 
mice 
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Chapter 1 : Introduction 
1.1 The renin-angiotensin system (RAS) cascade 
The renin-angiotensin system (RAS) has an important role in controlling blood pressure, fluid 
homeostasis and salt balance 1, 2. The reaction cascade typically starts in the juxtaglomerular (JG) 
cells of the kidney (Figure 1). There, the inactive prorenin (the renin proenzyme) is synthesized to 
be converted into active renin (an aspartyl protease) mainly in response to a decrease in blood 
pressure or increase in sympathetic activity. Mature renin is stored in granules in the JG cells and 
then released into the circulation while a smaller percentage remains in the kidneys to exert 
different intra-renal actions. Renin has been found to be synthesized in other sites such as brain, 
adrenal gland and visceral adipose tissue 3
Renin, in turn, works on the N-terminal of a liver plasma protein of type globulin called 
angiotensinogen (AGT), its only known substrate, to release a decapeptide, angiotensin I (Ang I). 
Ang I has mild vasoconstrictor effects but not sufficient to affect blood pressure 
. 
3
Further cleavage at the C-terminal of Ang I occurs via the angiotensin-converting enzyme (ACE), 
from the blood vessel endothelium in the lung, to form an 8 amino acids peptide, angiotensin II 
(Ang II), the most physiologically active component of the system  
.  
3
Ang II acts through cell surface receptors, Ang II type 1 or type 2 receptors (AT1R and AT2R), 
which are classified as G protein-coupled receptors 
.  
4. They have a wide distribution and are 
expressed by many cell types such as in the lung, liver, brain, kidneys and adrenals 2, 5
Ang II has been shown to act mainly via AT1R to produce most of its known physiological effects. 
For example, it elevates the arterial blood pressure by producing a potent arteriolar 
vasoconstriction as well as by stimulating thirst.  
.  
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In addition, it decreases renal sodium and water excretion as it stimulates the secretion of 
aldosterone from the cortex of adrenal glands 1, 2, 6. Ang II also plays a role in the regulation of cell 
growth, inflammatory responses and oxidative stress mainly via AT1R. On the other hand, AT2R 
has been found to mainly oppose AT1R action in many aspects, for example, it causes 
vasodilatation, inhibits cell differentiation, cell growth and apoptosis 7, 8. This receptor is highly 
expressed in foetal tissues and its expression levels decrease after birth 9
Recently, it was shown that other metabolites of Angs could have different biological activities. 
For example, Ang III is derived from Ang II by removal of one amino acid from its N- terminal. 
This has been shown to occur in the brain as well as the kidneys by the action of aminopeptidase A 
where it has been demonstrated to have a role in the regulation of blood pressure by acting through 
AT1R. Further degradation of Ang III by aminopeptidase N reveals Ang IV 
. 
10, 2
 Ang (1-9) can be produced from Ang I by the action ACE 2.  Ang (1-7) can then be produced 
from Ang (1-9) by the ACE or directly from Ang II through the activity of ACE 2 at its C-terminal 
. 
11, 12. In contrast to ACE, ACE 2 does not convert Ang I into Ang II and is unaffected by ACE 
inhibitors (ACEi). Ang (1-7) acts via a specific receptor (Mas receptor) to produce vasodilatation, 
natriuresis in addition to its cardioprotective effects 10
 
. 
 
3 
 
 
 
Figure 1: The renin-angiotensin system (RAS) cascade 
 
Classical RAS cascade starts by the production of Ang I from Angiotensinogen which further be 
converted into Ang II that works via two receptors; AT1R and ATR2. Other Angiotensins can be 
also produced such as Ang III, Ang IV, Ang (1-9) and Ang (1-7) that works through the Mas 
receptor. The (pro)renin receptor ((P)RR) was added recently to the cascade. Ang I, Angiotensin I; 
Ang II, Angiotensin II; Ang III, Angiotensin III; Ang IV, Angiotensin IV; Ang (1-7), Ang (1-7);  
Ang (1-9), Ang (1-9);  ACE, Angiotensin converting enzyme; ACE 2, Angiotensin converting 
enzyme 2; Mas R, Mas receptor; AT1R, Angiotensin receptor type 1; AT2R, Angiotensin receptor 
type 2; Amp. A, Aminopeptidase A; Amp. N, Aminopeptidase N.  
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1.2 Renin and prorenin  
As mentioned before, prorenin is the inactive renin precursor. Structurally, renin has 2 lobes with a 
cleft in-between carrying its active site with two aspartyl residues. Prorenin has 43 amino acid 
residues at its N-terminal called the prosegment that overlies the renin active site cleft and thus 
hinders the access to AGT 13
Prorenin can be activated by two mechanisms: 1) Irreversible proteolytic, by cleavage of the 
prosegment which occurs via both proconvertase 1 and cathepsin B, in vivo, mainly in the 
juxtaglomerular cells of the kidney 
.  
14, 15;  2) Reversible nonproteolytic, by unfolding the 
prosegment from the active site cleft via low pH or partial activation by low temperatures which 
have never been demonstrated in vivo 16, 17
Many tissues such as the eye, adrenal gland, adipose tissue, placenta and brain secrete inactive 
prorenin, but not active renin, into surrounding tissues and plasma 
.  
18-21. Of note, the kidney is the 
only known tissue to secrete active renin and as such, only prorenin can be detected in the 
circulation after bilateral removal of the kidneys 22. However, local RAS activity has been found in 
non-renal sites which suggests that there may be a way by which prorenin gets activated locally 23. 
Moreover, under physiological conditions, plasma prorenin levels are about 10 folds higher than 
renin 24. These are even higher, for undetermined reason, in certain physiological states such as in 
pregnancy and some pathological conditions as the diabetic nephropathy and retinopathy where 
plasma prorenin is used as a marker for microvascular complications 19, 24, 25
On the other hand, other non-renal tissues such as the heart and vascular wall are unable to 
synthesize prorenin and rely on the circulation as their major source of prorenin which would then 
be responsible for the local activation of the RAS 
. 
26, 27.  
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In subsequent studies, tissue prorenin was found to be activated in these organs and could lead to 
local production of angiotensin peptides 21, 28 although there were originally no known mechanisms 
for its activation in non-renal tissues. In addition, Ang II-independent actions of renin per se were 
found in cultured human mesangial cells 29
Taken together, this suggests that there is a mechanism by which prorenin in different tissues can 
be activated locally. Consequently, many have proposed a renin/prorenin (which we will 
collectively refer to as (pro)renin) binding protein (RnBP) or receptor to be implicated. 
. 
1.3 Renin binding proteins (RnBPs) 
Several RnBPs have been demonstrated. One of these was found to be similar to the enzyme N-
acyl-D-glucosamine 2 epimerase which can inhibit renin in vitro. However, its role in regulating 
renin activity in vivo was not determined 30. Another RnBP, the mannose-6-phosphate/insulin-like 
growth factor II receptor (IGF2R) was proposed. However, that receptor is now considered to be 
mainly a clearance mechanism for (pro)renin since binding was found to produce rapid 
internalization of the (pro)renin/receptor complex, followed by rapid prorenin cleavage to active 
renin which is then slowly degraded 31. Moreover, no extracellular or intracellular Ang production 
has been associated with this receptor 32
 
. 
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Chapter 2 : The (pro)renin receptor 
2.1 Discovery 
Studies in the last 5 years have reported the presence of a new promising (pro)renin receptor 
[(P)RR] which has been shown to activate the RAS as well as Ang II-independent signaling 
pathways 29, 33, 34. Using radio-labeled renin, Nguyen’s group identified a receptor that could 
specifically bind to both renin and prorenin with very high affinity in cultured human mesangial 
cells 29
In addition, an increase in 
. In contrast to the IGF2R, no renin internalization or degradation followed the binding.  
3H-thymidine incorporation without any effect on the cell count and a 
marked increase in plasminogen activator inhibitor-1 (PAI-1) antigen were observed subsequent to 
the binding. They suggested that renin produced mesangial cell activation which was characterized 
by a change in fibrinolytic capacity of the cells. Furthermore, they demonstrated that these effects 
were Ang II-independent as they were unaffected by either ACE inhibition or AT1R and AT2R 
blockade 33.  Subsequently, they cloned the receptor using an adult human kidney library and 
transfected the (P)RR cDNA into cells which lack the ability to bind renin 34
2.2 Structure 
. 
The (P)RR is a 45-kDa membrane protein that specifically binds (pro)renin although prorenin has  
a higher affinity for the receptor compared to renin 35, 36. Indeed, Nabi et al. showed that both rat 
prorenin and renin can bind to rat (P)RR  that was expressed by baculovirus expression system 
with a dissociation constant (Kd) values of 8 nm and 20 nm respectively 36. Structurally, (P)RR is   
a 350 amino-acids protein which has a small 20 amino acids intracellular domain (IC) and a single 
transmembrane domain (TM)34 as well as an extracellular domain (EC) where (pro)renin binds 37.  
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As mentioned earlier, the prorenin has a peptide sequence near its N-terminal called the 
prosegment which covers the renin active site. It was found that the prorenin can bind to its 
receptor via a small amino acid sequence of the prosegment called the handle region 37-39. 
However, renin, which lacks the prosegment, can bind to its receptor although the mechanism is 
still unclear. Nabi et al. demonstrated that a new segment present in both renin and prorenin, called 
the hinge region, could bind to the (P)RR  but with less affinity than that of the handle region 38. 
Later, it was discovered that the (P)RR is the full form of a smaller protein associated with the 
vacuolar H+-ATPase (V-ATPase) 40. Consequently, the name of the gene coding for the (P)RR is 
the ATPase, H+ transporting, lysosomal accessory protein 2 (ATP6AP2). The gene is located on 
the short arm of the X chromosome (Xp11.4) and encodes for a unique protein that gets further 
processed intracellularly 41
2.3 Distribution  
. 
In humans, (P)RR mRNA has been detected with high levels in the heart, placenta and brain while 
lower levels are present in the kidney and liver in addition to barely detectable levels in the lung 
and skeletal muscles 34.  In the human brain, it has been shown that the (P)RR mRNA is highly 
expressed specifically in the frontal lobe as well as in the pituitary. Moreover, cells of the human 
anterior pituitary paraventricular and supraoptic nuclei were positively stained for the receptor by 
immunohistochemistry and were found to co-localize with arginine vasopressin and oxytocin 42. 
The receptor has also been localized in the mesangium of renal glomeruli as well as in the sub-
endothelium of renal and coronary arteries of normal human kidney and heart 34
Interestingly, the (P)RR gene has been detected in isolated human adipocytes by Engeli et al. 
.  
43.  
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Furthermore, the same group detected the (P)RR mRNA in abdominal subcutaneous adipose tissue 
extracts of obese menopausal women 43. However, since the tissue extract is rich in blood vessels 
which also highly express the (P)RR mRNA, Achard V et al. later did further studies on the 
stromal areas and isolated stromal cells of  human visceral as well as subcutaneous adipose tissues. 
They were thus able to demonstrate specific synthesis of the functional (P)RR  in human adipose 
tissue 44
2.4 Signaling pathways of the (P)RR 
. 
2.4.1 Ang I production 
When renin binds to the (P)RR, it displays a four-fold increase in its catalytic efficiency to convert 
AGT into Ang I while prorenin shows a non-proteolytic activation 34. Thus, the (P)RR could have 
a very important role in the local production of Ang II in many tissues given that renin has been 
proposed to be the rate limiting step of the RAS (Figure 2) 34
The mechanism implicated in the non-proteolytic activation of prorenin observed with the binding 
to the (P)RR could be due to conformational changes 
.  
17, 35, 45, 46. Furthermore, renin activation has 
been proposed to be due to the proximity of the different components of the RAS, that is, Ang I 
produced by membrane-bound renin may be more easily converted to Ang II by membrane-bound 
ACE. However, a recent study investigating the presence of different forms of AGT proposes an 
alternate mechanism. The authors demonstrated that in both human and mice, AGT is present in 
two different forms, oxidized and reduced. The reduced form was found to be less easily 
transformed to Ang I as the cleavage site is buried within the structure of the molecule. 
Furthermore, the oxidized form was more susceptible to enzymatic cleavage by renin bound to the 
(P)RR which resulted in a 4-fold increase in Ang II production 47.  
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2.4.2 Ang II-independent signaling  
 2.4.2.1 Mitogen-Activated Protein Kinase (MAPK) 
It has been reported that binding of (pro)renin to its receptor triggers intracellular signaling which 
is Ang II-independent since it occurs in the presence of renin and ACEi as well as AT1R blockers. 
Ang II-independent pathways include rapid phosphorylation of the serine and tyrosine residues of 
the (P)RR and phosphorylation as well as activation of mitogen-activated protein kinase (MAPK) 
pathways such as extracellular signal regulated kinases 1 and 2 (ERK1/2), P38 and c-jun N-
terminal kinase (JNK), as well as heat shock protein 27 (HSP 27) (Figure 2) 48. The prorenin 
activation of the latter pathway has been shown to lead to changes in actin filament dynamics 
which are known to keep the integrity of the cell architecture and growth. Of note, no changes in 
intracellular Ca+2 or cAMP have been observed with (P)RR stimulation 34. Following ERK1/2 
activation via the (P)RR, an increase in the fibrogenic cytokine transforming growth factor (TGF)-
ß1 has been observed (Figure 2) 49. This in turn activates profibrotic molecules such as, PAI-1, 
fibronectin protein and collagen I, independently of Ang II 49, 50.  Furthermore, these effects were 
found to be blocked by TGF-ß1 antibody administration 50. It has recently been suggested that this 
occurs through an increased expression of Nox4 with a subsequent increase in superoxide anion 
production 51
2.4.2.2 Promyelocytic Zinc Finger (PLZF) 
.   
Another (P)RR signal transduction pathway which has been reported in vitro involves direct 
interaction between the C-terminal domain of the (P)RR and the promyelocytic zinc finger (PLZF) 
transcription factor 52. Following renin stimulation, the transcription of the p85α subunit of the 
phosphotidylnositol-3 kinase (PI3K-p85α) is activated which leads to translocation of the PLZF.  
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This in turn inhibits the transcription of the (P)RR, creating a short negative feedback loop (Figure 
2). Thus, high levels of (pro)renin could inhibit (P)RR expression and prevent excessive receptor 
activation 53
 
. 
Figure 2: Mechanism of action of (P)rorenin receptor 
Binding of the (pro)renin to the (P)RR leads to increased enzymatic activity of renin and renders 
prorenin non-proteolytically active which, taken together, increases the production of Ang II. At 
the same time, this binding leads to simultaneous activation of Ang II-independent intracellular 
signaling cascades. Binding sites for renin and prorenin to the receptor, hinge (yellow circles) and 
handle region (black rectangle), are also shown. ERK1/2, extracellular signal regulated kinases 1 
and 2; HSP 27, heat shock protein 27; p38 MAPK, mitogen-activated protein kinase p38; PAI-1, 
plasminogen activator inhibitor-1; PLZF, promyelocytic zinc finger; TGF-ß1, transforming growth 
factor ß1. Modified from Ahmed B. and Lavoie J.L. 48 
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2.4.2.3 Wnt/β-catenin signaling 
The implication of the (P)RR in the Wnt/β-catenin signaling pathway (Figure 3) has recently been 
reported. Wnt proteins have been shown to be essential for normal embryogenesis and regulate 
many cellular aspects in adult tissues. For example, dysregulation of Wnt signaling has been 
associated with cancer development 48, 54
In a study to understand the mechanism by which the Wnt receptors get activated, Cruciat et al. 
showed that the (P)RR was required for the activation of the Wnt-canonical pathway. Using a 
genome wide siRNA screen in HEK-293T cells (HEK cells expressing the large T-antigen of 
simian virus), they found that three siRNA directed towards the (P)RR resulted in inhibition of  
Wnt3 signaling at the level of, or upstream to the LRP 5/6 receptor 
.  
55. Moreover, they 
demonstrated that the (P)RR could bind to the components of the Wnt receptor complex, Frizzled 
and LRP 5/6, via it’s EC domain. They also found that the (P)RR acts as an adaptor between the 
LRP 5/6 receptor and the V-ATPase which induces LRP 5/6 phosphorylation and as such, activates 
the β-catenin pathway 55
On the other hand, (P)RR was also found to be  involved in the Wnt non-canonical pathway; the 
Wnt/PCP (planar cell polarity) 
. 
56, 57. Indeed, two groups have confirmed that the (P)RR can 
regulate PCP in Drosophila as well as the convergent-extension movements in Xenopus gastrulae. 
Interestingly, these events are independent of renin as neither the Drosophila nor Xenopus 
expresses renin 56, 57. 
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2.5 Alternate molecular forms of the (P)RR 
As mentioned previously, the receptor has 3 main domains: the TM, EC and IC domains. Previous 
studies investigating the receptor have mainly focused on the role of the full length (P)RR. Lately, 
it has become obvious that other forms of the receptor might also be playing important roles.  
2.5.1 (P)RR and V-ATPases  
Indeed, Ludwig et al. discovered by chance in 1998 a truncated form of the receptor composed of 
only the TM and the IC domains 58. They described the C-terminal part of the (P)RR protein as a 
8.9 kDa membrane-sector fragment (M 8-9) that associates with the V-ATPase present in 
chromaffin cell membranes (Figure 3). (P)RR and M 8-9 protein seem to be derived from the same 
(P)RR gene transcript. Accordingly, the (P)RR gene was named; ATP6AP2 58. V-ATPases are 
ATP-dependent proton pumps. Structurally, they are composed of a peripheral V1 and an integral 
V0 domain that are formed of 8 and 6 different subunits respectively. The V1 domain is 
responsible for ATP hydrolysis while the V0 domain translocates protons. Thus, the main roles of 
V-ATPases are the acidification of intracellular compartments, such as lysosomes and secretory 
vesicles, and proton pumping in different cell types such as in osteoclasts, macrophages and renal 
cells 59
Later, another functional link between the (P)RR and the V-ATPase was demonstrated by Advani 
et al. as they first reported a high expression of the (P)RR on the apical membrane of  rat collecting 
ducts intercalated A cells as well as in the convoluted and distal tubules of human kidneys 
. 
60. They 
further determined the co-localization of (P)RR with the V-ATPase B 1/2 in this subtype of 
intercalated cells 60. Moreover, the implication of the (P)RR/V-ATPase interaction in the (P)RR 
Ang II-independent pathways has been shown.  
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They demonstrated that the (P)RR ERK1/2 activation was attenuated when they pre-treated Madin 
Darby canine kidney cells, a collecting duct/ distal tubule lineage, with  bafilomycin; a selective  
V-ATPase inhibitor 60
Lately, additional data supporting the (P)RR/V-ATPase relation has been reported. For example, it 
was found that mice deficient in the (P)RR specifically in cardiomyocytes, developed severe heart 
failure and died by 3 weeks of age, although no cardiac anomalies could be detected at birth. 
Interestingly, cardiomyocytes from these knock-out mice showed depleted levels of the V0 domain 
without any effect on the V1 domain of the V-ATPase. This could be reproduced in cultured 
embryonic fibroblasts with specific ablation of the (P)RR gene 
.  
40. As a result, (P)RR loss in 
cultured cells impaired vesicular acidification. In addition, cultured cardiomyocytes treated with 
bafilomycin showed similar phenotype to what was observed in isolated cardiomyocytes from 
knock-out animals 40. Similarly, two groups reported that the (P)RR/V-ATPase is crucial for 
podocyte function and survival using mice with specific deletion of the (P)RR in podocytes 61, 62. 
Knock-out mice were born without any detectable kidney abnormalities but developed a disruption 
of the glomerular filtration barrier that lead to a nephrotic syndrome which produced sever renal 
failure. As such, mice died as early as 2 to 4 weeks of age and their podocytes showed marked foot 
process effacement, alteration of their actin cytoskeleton, reduction of the slit diaphragm proteins 
and further numerous autophagic vacuoles. Interestingly, and in line with what was noticed with 
cardiac specific deletion of the (P)RR, (P)RR deletion in podocytes was found to be associated 
with a suppression of the V0 domain of the V-ATPase. This produced V-ATPase dysfunction that 
resulted in deacidification of intracellular vesicles.  Moreover, previous abnormalities could also 
be reproduced by treating cultured podocytes with bafilomycin 61, 62.  
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Taken together, we can conclude that the (P)RR plays an important role in regulating V-ATPase 
activity and that the V-ATPase is implicated in (P)RR Ang II-independent signaling.  
2.5.2 Soluble form of the (P)RR 
Recently, a truncated soluble form of the (P)RR [s(P)RR] of 28 kDa  that contains only the EC 
domain has been described. It is present in both plasma and urine and retains the ability to bind 
renin and prorenin (Figure 3) 63, 64. Similarly to the full length (P)RR, the s(P)RR has been shown 
to activate prorenin and thus stimulate the production of Ang I 64-66 although there is no data 
concerning its impact on renin activity. Studies have suggested the possible implication of several 
enzymes such as furin or metalloproteases in the production of the s(P)RR 63, 65. If we take into 
consideration the data showing that oxidized AGT is more readily cleaved by renin bound to the 
(P)RR, we can conclude that the s(P)RR may constitute a novel mechanism for the development of 
hypertension as well as other RAS-associated diseases.  
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Figure 3: (P)RR and Wnt signaling 
 
(P)RR acts as an adaptor between LRP 5/6 and V-ATPase (1) the later generates a proton gradient 
(2) that is essential for the phosphorylation and activation of LRP 5/6 (3) which in turn activates  
β-catenin signaling. LRP 5/6, low-density lipoprotein receptor-related protein 5/6; (P)RR, 
(Pro)renin receptor; Pi, phosphate ion. Modified from Ahmed B. and Lavoie J.L.48
 
. 
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2.6 Animal models of the (P)RR 
2.6.1 Deletion of the (P)RR 
Generating a knock-out model of the (P)RR is an extremely interesting tool to study the receptor’s 
physiological roles. In fact, it has been found that ubiquitous deletion of the receptor is lethal, 
which reflects the importance and necessity of the (P)RR gene in embryonic development 41
For instance, mutation of the (P)RR gene by gene trap in zebrafish embryos has been shown to be 
lethal before the end of embryogenesis and was associated with developmental abnormalities 
including neuronal cell death as well as body and eye hypopigmentation 
.  
41. As mentioned earlier in 
the text, the (P)RR was found to be implicated in the Wnt signaling pathways which could explain 
these results. In contrast, tissue specific deletion of the receptor is not developmentally lethal 
although animals develop lethal defects after birth. For instance, knocking down the (P)RR in mice 
cardiomyocytes produced fatal heart failure at 3 weeks of age 40 while  specific deletion of the 
(P)RR in podocytes resulted in severe renal failure and animal death by 2 to 4 weeks of age 61, 62
2.6.2 Overexpression of the (P)RR 
. 
Transgenic animals which overexpress the (P)RR gene are an interesting alternative that has been 
employed to define the pathogenic effects and evaluate the in vivo relevance of the receptor. For 
instance, rats overexpressing the human (P)RR ubiquitously presented with slow progressive 
nephropathy produced mainly by Ang II-independent signaling. Indeed, these rats showed 
significant proteinuria with aging and glomerulosclerosis at 28 weeks of age as well as enhanced 
renal TGF-ß1 expression without any elevation in renal Ang II, blood glucose or blood pressure 67. 
In contrast to imidapril, an ACEi, complete prevention of all mentioned symptoms could be 
achieved by chronic administration of a (P)RR blocker (PRRB), also known as the handle region 
peptide 67. Moreover, renal enhancement of ERK, p38, and JNK immunostaining was observed. 
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The ERK and p38 activation were also completely inhibited by the PRRB while JNK activation 
was only attenuated but all three were unaffected by ACEi 67. By using the same model, it was 
shown that transgenic rats had no changes in their blood pressure however their renal cortical 
cyclooxygenase-2 (COX-2) mRNA and protein levels were significantly increased. In addition, 
urine sodium excretion was found to be also increased which could be explained by activation of 
both RAS dependent and independent mechanisms as a result of increased PRR expression. 
Interestingly, COX-2 inhibition produced a significant decrease in renal cortical blood flow 
specifically in the transgenic animals 68
On the other hand, rats overexpressing human (P)RR specifically in vascular smooth muscle  
developed progressive cardiovascular symptoms. Rats developed normally but exhibited 
spontaneous cardiovascular phenotypes at the age of 6 months such as marked increase in systolic 
blood pressure and an unexpected elevation in heart rate 
. Given that cortical COX-2 has been suggested to be 
implicated in diabetic hyperfiltration, these results suggest that the (P)RR may be involved in this 
effect. 
69. These symptoms were aggravated with 
age and earlier appearance of these symptoms could be observed in rats with higher transgene 
expression. In addition, this was accompanied by an increased plasma aldosterone levels as well as 
a significant increase in plasma aldosterone/renin ratio 69. This demonstrates that aldosterone 
production was enhanced via the increased adrenal Ang II as a result of (P)RR overexpression 
without changing the renin levels.  
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Chapter 3 : Obesity 
3.1  Epidemiology and definition 
The dramatic increase in the prevalence of obesity among Canadians over the past 30 years has 
been deemed to constitute an “epidemic.” In 2011, 18.3 %, approximately 4.5 million, of Canadian 
adults were reported to be obese 70. In 2010, the IASO/IOTF (International Obesity Taskforce) 
analysis revealed that approximately 1.0 billion adults are overweight and a further 475 million are 
obese worldwide. Globally, 150 million school-aged children were found to be overweight and 50 
million were obese 71
WHO defines obesity as an abnormal or excessive fat accumulation that presents a risk to health. 
WHO classifies obesity using the body mass index (BMI) which is calculated by dividing the body 
weight by the square of the height (Kg /m
. Indeed, the World Health Organization (WHO) refers to the escalating 
global epidemic of obesity as “globesity,”  
2). According to WHO, people with BMI equal to or 
greater than 25 are considered overweight while obese individuals are characterized by a BMI 
equal to or greater than 30. Obesity is a multifactorial problem in regards to its etiology. Many 
theories have been proposed in trials to find a defined etiology such as gene-environmental and 
gene-behavioral interactions. However, the corner stone for occurrence of obesity remains the 
increased energy intake in the form of caloric consumption over the energy expenditure 72. Lately, 
many factors were found to be implicated in increased caloric intake such as increased portion size, 
ready-made food and sweetened beverages as well as attractive advertising to promote them 72. 
The continuous change in life style towards a more sedentary behavior leads to a decrease in 
energy expenditure 72.  
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Several studies have reported that an increase in BMI is positively correlated with higher mortality 
rates 73, 74 as a result of the increased the incidence of many health problems 75. For instance, 
obesity is strongly associated with the development of type II diabetes in men and women of all 
ethnic groups 76-78 by causing insulin resistance. One of the proposed mechanisms for this effect is 
the increased production of the adipokines (elements that are produced by the adipose tissue) that 
enhance insulin resistance, such as resistin, and the decrease in those that stimulate the insulin 
sensitivity, such as adiponectin 79. Another theory is that the increased secretion by adipose tissue 
of inflammatory chemokines enhances macrophage activation and infiltration into the adipose 
tissue. Activated macrophages in turn secrete different cytokines that affects the insulin sensitivity 
80. As obesity is associated with an increase in circulatory and visceral free fatty acids, excess fatty 
acids also promote the development of insulin resistance in the liver as well as in skeletal muscles 
79. Obesity is also associated with a disturbed lipid profile (dyslipidemia) in the form of decreased 
levels of circulatory high density lipoprotein (HDL) cholesterol while increased levels of 
circulatory triglycerides, cholesterol, low density lipoprotein (LDL) cholesterol, very low density 
lipoprotein (VLDL) cholesterol and apolipoprotein B 75. Moreover, it has been reported that 
obesity is associated with elevated risk for cerebrovascular strokes 75. For example, a study 
reported that a BMI above 30 Kg /m2 was associated with increased the risk for total and ischemic 
but not for hemorrhagic strokes 81. Also, obese individuals have been reported to be more prone to 
develop heart diseases 75. For instance, the risk of developing heart failure was found to be 
increased by x-fold in obese subjects compared to those with a normal BMI 82. Obesity is also a 
major risk factor for some respiratory diseases such as obstructive sleep apnea 75. In addition, 
pregnant obese women are at higher risk of developing gestational diabetes and preeclampsia as 
well as more subject to caesarean sections 83. Moreover, the incidence of other health problems 
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was found to be increased with obesity such as the osteoarthritis, psychological disorders, and even 
some types of cancers such as breast, colon, esophagus and kidney 72
3.2 Obesity treatment 
. 
Many treatments for obesity have been proposed such as lifestyle modifications including dieting 
and exercise, psychological therapies as well as bariatric surgeries including Roux-en-Y bypass or 
gastric banding 84. In addition, several anti- obesity drugs have been tested to control weight gain 
but have been stopped due to the increased risk of developing cardiovascular disorders, such as  
desoxyephedrine, phentermine and diethylpropion (amphetamine derivatives) as well as 
fenfluramine and dexfenfluramine (serotonin-releasing agents) 84. Sibutramine (noradrenaline and 
serotonin-reuptake inhibitor) was believed to reduce weight gain by decreasing food intake and 
increasing energy expenditure, but it was reported to have serious side effects on the 
cardiovascular system. For example, long term use of Sibutramine in subjects with high 
cardiovascular risk was found to increasing the risk of nonfatal myocardial infarction and nonfatal 
stroke 85. Conversely, Orlistat has been approved as an anti-obesity drug that decreases fat 
absorption by inhibiting the pancreatic lipases 86
3.3 White adipose tissue 
. Apart from associated gastrointestinal symptoms 
such as bloating and diarrhea, Orlistat doesn’t seem to have any serious side effects and as such, is 
a more promising treatment option. 
White adipose tissue (WAT) (Figure 4) is formed of adipocytes and a stromal vascular 
compartment or fraction where the preadipocytes are located 87. Almost all adipose tissue in the 
adult human body is WAT with a very wide distribution with the exception of certain tissues such 
as the eyelids, the penis and the scrotum. WAT can be divided according to the pattern of 
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distribution into subcutaneous and internal fat. Subcutaneous fat lies between the skin dermis and 
the outer layer of the muscles (fasciae). Internal fat includes visceral fat and non-visceral fat such 
as bone marrow. Visceral fat includes all intra-abdominal and pelvic fat such as omental, peri-
renal, mesenteric fat as well as ectopic fat sites including heart, liver and muscles. The distribution 
and density of adipose deposits depends on the age, sex and ethnic group 88, 89. For instance, the 
subcutaneous fat of women is noticed to be located mainly in the buttocks, thigh (gluteofemoral) 
and breast while around the abdomen (lumbosacral), neck and upper arm for men and this 
distribution becomes more obvious with age 89. Of note, mature adipocytes count no more than 
half of the total cell content since WAT also contains other cell types such as fibroblasts, 
endothelial cells, preadipocytes, and macrophages 90
 
. 
 
Figure 4: White adipose tissue 
 
Hematoxylin and eosin stained section of mesenteric fat showing unilocular white adipocytes. Fat 
dissolved during the staining and cells appeared as empty spaces with small rim of cytoplasm and 
peripheral nuclei. Cells are separated by connective tissue that entangles fibroblasts and blood 
vessels. Modified from DiFiore’s Atlas of histology 91.  
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Adipose tissue cells are derived initially from the mesenchymal stem cell (Figure 5). As can be 
seen, a series of differentiation cascades that end by the production of mature adipocytes are 
required and are under the control of several transcription factors 89.  The peroxisome proliferator-
activated receptor γ (PPARγ) is one of the key transcription factors. It is a very important nuclear 
receptor that has been found to induce adipogenesis92 and plays a role in determining WAT 
distribution 93, 94
 
. 
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Figure 5: White and brown adipocytes’ differentiation 
 
The differentiation cascade of adipocytes from mesenchymal stem cells which is enhanced by 
several transcription factors is presented in this figure. CREB: (cAMP-response-element)-binding 
protein; PPARγ: peroxisome proliferator-activated receptor-gamma; C/EBPs: CCAAT/enhancer-
binding proteins; PGC-2: peroxisome proliferator-activated receptor-gamma co-activator-2; FABP: 
fatty-acid binding protein; PGC-1α: peroxisome proliferator-activated receptor-gamma co-
activator-1alpha; PRDM16: PR domain containing 16. Modified from obesity science to practice 
89
 
. 
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The main function of WAT seems to be energy storage that could easily be released during periods 
of negative energy balance and supply the different organs with fatty acids to be oxidized 95. The 
WAT mass is determined by both the number and the size of adipocytes. It was proposed that 
during states of positive energy balance, adipocytes first become hypertrophic (increase in size) 
and then hyperplasia follows (increase in number). As such, adipocyte hyperplasia occurs only 
when adipocytes attain their maximal capacity of expansion as mentioned above. This capacity 
seems to be genetically determined 96
However, WAT has other roles; for example, it acts as a heat insulator as well as it protects and 
supports internal organs 
.  
97.  It was also found that WAT plays an important role in several 
homoeostatic mechanisms such as the regulation of blood cell precursors, immunity and insulin 
sensitivity 97. Moreover, it has been found in the last decade that adipocytes are able to release 
many factors,  named adipokines, that play an important role not only in the regulation of energy 
homoeostasis but also on other physiological processes 98. For instance, it has been found that 
WAT secretes a 16-kDa protein called leptin 99 which was found to be a product of the Ob gene. 
Mutation of this gene results in severe obesity as can be seen in the Ob/Ob mice 100, 101. In addition, 
plasma leptin levels correlate directly with adipocyte size and body fat mass thus it increases 
markedly with the development of obesity in both human and rodents 99.  Indeed, leptin informs 
the brain about the energy status of the body. For example, in positive energy balance state, leptin 
crosses the blood brain barrier to stimulate its receptor in the brain which is highly expressed in the 
hypothalamic neurons 102, 103. Thus it inhibits the orexigenic and enhances the anorexiogenic 
pathways of the hypothalamus to strongly suppress food intake and increase the energy 
expenditure. However, as leptin levels usually increase with the development of human and rodent 
obesity, this strongly suggests the development of leptin resistance in this condition 102, 103.  
25 
 
 
Leptin also has other metabolic functions. For example, it was found that leptin can suppress the 
expression of the insulin gene as well as insulin secretion in human pancreas 104
Another adipokine called adiponectin is also secreted by white adipocytes. Conversely to what is 
found with leptin, adiponectin levels were found to be decreased with the development of obesity 
and to be increased by food deprivation 
. 
105. Adiponectin acts through its receptors, AdipoR1 and 
AdipoR2, which are widely distributed in skeletal muscles and liver respectively. In skeletal 
muscles, adiponectin increases fatty acid oxidation and glucose uptake 105. Decreased adiponectin 
levels in humans and total ablation of adiponectin in rodents were associated with the development 
of hepatic insulin resistance, inflammation as well as vascular injuries thus it also has an insulin 
sensitizing action 105
3.4 Brown adipose tissue  
.  
Brown adipose tissue (BAT) in mammals plays a role in the regulation of both basal and inducible 
energy expenditure through thermogenesis. BAT cells have a lot of mitochondria that express a 
specific type of protein called the uncoupling protein 1 (UCP-1) at their inner membranes.   UCP-1 
allows the dispersion of the electro-chemical gradient that is generated through the respiratory 
chain in the form of heat rather than ATP, a process called uncoupling of the oxidative 
phosphorylation 106. In rodents, BAT is found to be abundant in newborns especially in their inter-
scapular areas 107. Of note, brown adipocytes can also be found in other WAT sites especially in 
the inguinal, retroperitoneal and peri-ovarian region of reproductive fat. Interestingly, the number 
of brown adipocytes as well as the expression of UCP-1 was found to be increased in these sites 
after cold exposure 108. In humans, it has been thought for a long time that BAT is found only in 
newborns but it has been shown lately that adults also have functional BAT 107.  
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Chapter 4 : The renin-angiotensin system and obesity  
4.1 Human studies 
A study reported that, plasma AGT concentrations are significantly and positively correlated with 
BMI as well as plasma leptin levels in normotensive non-obese young men suggesting a relation 
between adipose mass and circulating AGT levels 109. Many reports showed the positive 
correlation of circulatory AGT and obesity 110-113. It was also found that the expression of the AGT 
gene was increased in subcutaneous adipose tissue of obese men in correlation to the body weight 
114. In addition, the expression level in subcutaneous and omental fat was positively correlated with 
an increase in waist circumference 115. Another group observed an increase in circulating RAS 
activity with a decrease in adipose tissue AGT gene expression in obese menopausal women 
compared to their lean counterparts 43. However, although AGT expression has sometimes been 
found to be decreased, it is thought that the increase in adipose mass produces an overall increase 
in AGT adipose tissue content which would contribute to the increase in circulating AGT observed 
with obesity. Interestingly, in this study a significant decrease in RAS activity and further 
reduction in adipose tissue AGT expression were noticed after only 5 % reduction in body weight 
43. In line with these results, a study using Telmisartan, an AT1R antagonist, demonstrated the 
implication of the RAS on the distribution of body fat in patients with metabolic syndrome. 
Indeed, Telmisartan lead to significant and selective decrease in visceral but not subcutaneous fat 
which was associated with an improvement in insulin sensitivity 116. Similar results were obtained 
by another group also using Telmisartan when administered to Japanese hypertensive patients 
which was associated with an increase in serum adiponectin levels 117.  
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It was also found that the use of Enalapril (an ACEi) for 16 weeks in moderately hypertensive 
patients was associated with a significant reduction of their body weights 118
4.2 Animal studies 
.   
Many in vivo animal studies have found that the RAS might play a role in the pathogenesis and 
occurrence of obesity. For instance, renal ACE activity was found to be increased in association 
with obesity development in mice 119. Moreover, it was noticed that mice with ubiquitous AGT 
deficiency were resistant to weight gain in response to both a normal and high fat diet which may 
be as a result of their significant increase in locomotor activity 120. No changes in the dietary fat 
excretion were detected while an altered white adipose tissue development in the form of adipocyte 
hypotrophy and a decrease in their triglyceride content with an associated decrease in fatty acid 
synthase (FAS) activity were shown 120. It was reported that AT1Ra/AT1Rb null mice showed 
slower rate of body weight gain after birth which was mainly as a result of a decrease in fat mass 
121. Another study showed that mice lacking AT2R were also resistant to diet induced weight gain 
and obesity as well as obesity related glucose intolerance 122. They also showed increased levels of 
lipid oxidation. As a result, adipose tissue displayed adipocyte hyperplasia and hypotrophy. The 
authors reported that the small sized adipocytes  could be explained by the associated decrease in 
the activity of the FAS in addition to decreased gene expression of PPARγ, the lipoprotein lipase 
(LPL) as well as the fatty acid transporters CD36 and fatty acid protein (aP2) which stimulate the 
fatty acid uptake and storage 122. Conversely, the authors couldn’t find the exact mechanism 
implicated in the adipocyte hyperplasia since Ang II has been reported to have a stimulatory effect 
on preadipocytes differentiation via AT2R 123.   
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However, they suggested that Ang II may have an inhibitory effect on preadipocytes proliferation 
in vivo via the AT2R as what was reported in smooth muscles and endothelial cells 122
Moreover, it was observed that knocking down the AT1Ra in mice attenuated the high-fat diet 
induced obesity, weight gain and adiposity as a result of the increased energy expenditure and 
sympathetic activity without any changes in food intake. In addition, these mice were protected 
from some components of the metabolic syndrome as they had low blood pressure and showed an 
attenuation of the impaired glucose tolerance and insulin resistance as compared to their wild type 
littermates 
.  
124
On the other hand, in vitro studies revealed conflicting data about the role of AT1R and AT2R in 
adipocytes. For instance, AT1R but not AT2R protein was detected throughout the differentiation 
process of 3T3-L1 preadipocytes
. Thus it could be concluded that AT1R and AT2R may have synergistic effects in 
regards to adipose tissue development in vivo. 
125 while a hypertrophic effect on 3T3-L1 and human adipocytes 
in primary culture via AT2R was also reported 126
Of note, an inhibitory effect of Ang II through the AT1Ra on human preadipocytes conversion in 
primary culture was reported 
. 
127, 128 while other group showed Ang II stimulatory effect on Ob1771 
mouse adipocytes differentiation through AT2R 123
In another study, mice lacking the renin gene presented with lighter body weights compared to 
their wild-type littermates and these differences were accentuated by the administration of a high-
fat diet. This was associated with an increase in metabolic rate as well as a decrease in intestinal 
dietary fat absorption 
. The discrepancy of the results might be 
explained by the variability in adipocyte sources and /or the experimental duration.    
129. In addition, no changes in food intake or in locomotor activity were 
observed and they were more insulin sensitive compared to their wild-type littermates 129.  
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Similarly, mice deficient in the ACE gene were leaner as they presented with a reduced body 
weight and showed less fat depots. This was associated with an increase in their total and resting 
energy expenditure with no changes in their food consumption and locomotor activity although 
their fecal fat excretion was not affected 130. The controversy in regards to fat excretion data may 
be due to the different methods used. For instance, chloroform: methanol solution was used for 
ACE null mice versus petroleum benzene for AGT knocked out mice 130, 120 while fecal acid 
steatocrit was measured in mice lacking the renin gene 129
As such, it was hypothesized that the administration of RAS blockers might show similar results to 
what had been observed with the deletion of the different RAS genes. Indeed, Sprague–Dawley 
rats receiving a normal diet that were treated with Perindopril, an ACEi, had a reduced weight gain 
as well as a decreased plasma leptin levels compared to the untreated group. This was not 
associated with any changes in their food intake and was considered to be mainly as a result of a 
reduction in their body fat mass as measured by Dual energy X- ray absorptiometry (DEXA) with 
no changes in their lean or bone mass 
.  
131. Authors suggested that these effects may be due to a 
reduction in both plasma and tissue angiotensin which is known to promote adipocytes 
differentiation and adipogenesis although angiotensin levels were not assessed. Similar results 
were observed in Long Evans rats which received another ACEi, captopril, on either normal or 
high-fat diet but with noticeable changes in food intake 132. Administration of the perindopril in the 
drinking water of Sprague–Dawley rats since birth was also associated with a decrease in body 
weight and food intake 133. It has been suggested that the discrepancy in the food intake results 
might be explained by the difference between each ACEi to access and affect the brain nuclei at 
different doses 132. Indeed, it has been shown that chronic treatment, over ten months, with 
captopril or irbesartan, an AT1R blocker, in NZO/BL6 F1, a genetic mouse model of the metabolic 
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syndrome, was beneficial in preventing obesity and hyperinsulinemia while reducing hypertension 
without changing food intake 134
 
. Authors proposed that blocking the RAS might increase insulin 
secretion and thus enhance catabolism as suggested by the increased plasma urea levels with 
normal kidney functions in the captopril treated group. Based on these studies, we can conclude 
that the RAS has a role in the pathogenesis of obesity in rodents.    
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Chapter 5 : Adipose tissue renin-angiotensin system  
5.1 Local tissue RAS  
It was demonstrated that the RAS is not only active systemically but that there are also complete 
RAS in many tissues (Figure 6). Indeed, critical components of the RAS have been described in 
several organs such as the brain, kidney, gonads, heart, pancreas and adipose tissue (Figure 6) 2. 
This strongly suggests a potential autocrine and paracrine role of the RAS 135. For example, brain 
Ang II has been found to act as a neurotransmitter 136. Moreover, local RAS could be involved in 
different pathologies. For instance, brain and kidney RASs have been demonstrated to contribute 
to the development of hypertension 2
 
. 
Figure 6: Expression of the RAS 
Sites of expression of the different components of the RAS are shown. Classical sites of synthesis 
for the endocrine RAS are in bold. AGT, Angiotensinogen; ACE, Angiotensin-converting enzyme; 
AT1R, Angiotensin receptor type 1; AT2R, Angiotensin receptor type 2. Modified from Lavoie 
J.L. and Sigmund C.D. 2. 
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5.2 Adipose tissue RAS and obesity 
Local RAS in adipose tissue has recently been a rich research area. In an early report, transgenic 
mice which overexpressed human AGT under the control of its own promoter showed high 
expression of the gene mRNA in their white as well as brown adipose tissue with stronger 
expression in male mice compared to females 137. In another report, the AGT mRNA expression 
was found to be 4 times higher in visceral fat compared to subcutaneous fat of human subjects with 
a BMI of less than 30 kg/m2. In obese subjects, AGT gene expression was significantly higher than 
leaner subjects in subcutaneous adipose without noticeable changes in visceral fat 138. In line with 
these results, another group found that AGT gene expression and protein secretion were 
significantly higher in visceral as compared to subcutaneous isolated adipocytes from normal male 
rats. Interestingly, a 50% reduction in the AGT secretion from different adipose tissue depots 
occurred after castration and was reversed by the administration of testosterone 139. Furthermore, 
several studies have shown that the high expression of AGT in adipose tissues and its constitutive 
excretion from mature adipocytes was present in rodents as well as in humans 140. Indeed, adipose 
tissue was found to be responsible for up to 30% of the circulating levels of AGT in rodents 141. 
Moreover, targeted AGT overexpression in mice adipose tissue was found to be associated with 
obesity development and hypertension 141. It is important to know that adipose tissue also 
expresses other components of the RAS such as renin, ACE and ACE2. As such, this contributes to 
the synthesis of Ang II and other angiotensin peptides in the adipose tissue 123, 142. Hence, adipose 
tissue not only contributes to Ang II production but it also allows for its autocrine and paracrine 
action since AT1R, AT2R and MasR  are expressed in both adipocytes and periadipocytes 143.  In 
addition, it was observed that the production of adipose tissue AGT is concomitantly increased 
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with the development of both genetic and diet induced obesity not only in rodents 144, 145 but also in 
humans 114
Ang II enhances the lipogenesis in adipocytes by increasing the activity
.  
146 and the gene 
transcription of the adipocyte FAS through the AT2 receptors 126, 147. It also stimulates the activity 
of other lipogenic enzymes such as glycerol-3-phosphate dehydrogenase 146. Through the same 
receptor, Ang II was also found to work as a lipogenic hormone since it promotes the accumulation 
of triglycerides in murine adipocytes and in human adipose cells in primary culture which 
promotes adipocyte growth 126.  Another group found that Ang II had a dose dependent anti-
lipolytic effect on human subcutaneous adipose tissue and skeletal muscle in both normal weight 
and obese subjects 148. Later, the same authors found that this effect occurred mainly via AT1R 149. 
Furthermore, an enhanced lipolytic activity with a subsequent increase in plasma free fatty acids 
and significant decrease in epididymal fat weight were noticed in fasted mice treated with 
valsartan, an AT1R antagonist 150. Of note, Ang II was found to enhance the differentiation of 
preadipocytes into mature adipocytes by different mechanisms via both AT1R 142 and AT2R 123, 
151
5.3 Adipose tissue RAS and insulin sensitivity 
. Overall, Ang II seems to play an evident role in enhancing adipocyte lipid storage and 
expanding white adipose tissue by different mechanisms. 
Generally, acute Ang II administration is associated with an improved insulin sensitivity and 
adipocyte glucose consumption in rodents as well as in type 2 diabetic subjects. Conversely, 
chronic Ang II infusion in rats was found to induce significant insulin resistance and impaired 
insulin signaling such as, reduced adipocyte and skeletal muscle glucose uptake due to increased 
oxidative stress 152.  
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Locally, overexpression of AGT in mice adipose tissue was found to be associated with increased 
insulin resistance in parallel to obesity development 153
 
.  
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Chapter 6 : Hypothesis 
As mentioned above, RAS activation is associated with obesity development. As a new member of 
the RAS, the (P)RR was found to increase renin enzymatic activity and thus stimulates the 
production of Ang I, and as a result, Ang II. In addition, the (P)RR was found to have specific  
Ang II-independent signaling pathways as mentioned earlier. Therefore, we expect that the (P)RR 
might also have a role in regulating body weight and obesity development although little is known 
about this role.  
We have recently demonstrated in our laboratory that the (P)RR mRNA levels are increased 
specifically in white adipose tissue depots in a mouse model of diet-induced obesity and that 
systemic administration of a (P)RR blocker reduces weight gain and appetite 154
 
. Furthermore, this 
is accompanied by a normalization of many circulating metabolites such as free fatty acids, 
triglycerides and glucose although the exact mechanism is unknown. Hence, to determine the 
implication of adipose tissue in this novel role of the (P)RR, mice deficient for this receptor (AP2-
KO) specifically in their white adipose tissue were studied.  We hypothesize that knocking down 
the receptor in white adipose tissue will decrease weight gain and prevent the development of 
obesity and its related complications, such as type II diabetes.  
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Chapter 7 : Materials and Methods 
7.1 Animals 
Mice deficient for the (P)RR in their white adipose tissue were generated using the Cre/Lox 
technology. (P)RR floxed mice (a generous gift from Merck Frosst Canada) in which exon 2 of the 
ATP6AP2 gene was flanked between loxP sites, were bred with AP2-Cre recombinase mice (AP2-
Cre mice; Jackson Laboratories) that express the Cre-recombinase enzyme under the control of a 
white adipocyte promoter (Figure 7).  
 
 
 
Figure 7: Genotype strategy for AP2-KO mice.  
Cre- recombinase enzyme excises the floxed exon 2 of ATP6AP2 gene.  
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The produced Cre+/ PRR-L +/- mice specifically lack the (P)RR in adipose tissue (AP2-KO). 
Since the (P)RR gene is carried on the X- chromosome, we had homozygote complete knock-out 
males while heterozygote partial knocked out females.  We used Cre-/ PRR-L -/- male and female 
littermates as control mice (wild-type). We also looked at Cre+ and PRR-L +/- mice and they were 
not different then the Cre-/ PRR-L -/- wild-types. 
Animals were maintained on 12-hour light/dark cycle with free access to food and water. At 10 
weeks of age, mice were separated one per cage to acclimate to this housing condition before the 
start of the experiments. At 12 weeks of age, we started monitoring mice body weight gain, food 
and water consumption on a weekly basis.  
Mice were divided into 2 groups, AP2-KO and wild-type (WT) mice, both adult males and 
females, were maintained for 4 weeks on a normal diet; standard laboratory chow (2018; Teklab 
Premier Laboratory Diets, Madison, WI) ad libitum. One group of females was placed for an 
additional 6 weeks on a high-fat/high carbohydrate (HF/HC) diet (Bio serv; 545 kcal/100g; 60% 
fat) to induce obesity. Care of the mice used in these experiments complied with standards for the 
care and use of experimental animals set by the Canadian Council for the Protection of Animals, 
and all procedures were approved by the University Animal Care and Use Committee at the 
CHUM Research Center.  
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7.2 Genotyping 
Tail snips were obtained and DNA was purified in order to genotype all mice using polymerase 
chain reaction (PCR). For DNA extraction, tails were digested by heating the samples for 60 
minutes at 90°C in 100 µl of basic digestion buffer (pH 12.0) (25mM NaOH and 0.2mM EDTA 
disodium dissolved in sterile water) 155. Samples were preserved at -20o
PCR was done to detect the presence of both Ap2-Cre recombinase and the (P)RR loxP genes. A 
final volume of 14 µl was used for the PCR reaction of the Ap2-Cre transgene which contained 0.5 
μl of DNA in addition to 20 µM of each of the 4 primers, 10x reaction buffer, 10 µM dNTP 
(deoxynucleotide phosphate) mix (CTP, GTP, ATP and TTP), 50 mM MgCl
C for future analysis.  
2
 
, 0,1 μl of 5 U/μl Taq 
polymerase and 7.2 μl of sterile water. The sequences for the primers used are indicated in table 1. 
The DNA was amplified over 35 cycles with a primer annealing temperature of 51°C. DNA was 
then loaded on 3% agarose gel and migrated for 30 minutes at 100 volts. Positive samples showed 
a band around 100 bp in addition to the internal control band which was around 324 bp (Figure 8). 
 
Figure 8: A gel image for the Ap2-Cre recombinase genotyping PCR 
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Table 1: Primers for Ap2-Cre recombinase and (P)RR loxP genes 
 
Ap2-Cre recombinase 
oIRM0042  5' CTA GGC CAC AGA ATT GAA AGA TCT -3' 
oIRM0043   5' GTA GGT GGA AAT TCT AGC ATC ATC C -3' 
oIRM1084   5' GCG GTC TGG CAG TAA AAA CTA TC -3' 
oIRM1085    5' GTG AAA CAG CAT TGC TGT CAC TT  -3' 
(P)RR loxP 
2271 5' AGCACTCTCTTCCAGGTATGTTGTG 3' 
2273 5' CTGGATCCCGGAGCATGGGTAAAGG 3'  
2274 5' CAGGTGTGCTGCTATTAATAGG 3' 
2276 5' GCCCCTCTCTTACAGTTCTATCAGT 3' 
 
For the (P)RR loxP amplification, 0.5 µl of DNA was added to a final volume of 25 µl mix as 
mentioned before but with the use of 100 µM of each of the primers. The sequences of the used 
primers are indicated in table 1. 
The PCR was run over 30 cycles with an annealing temperature of 62°C. The DNA was also 
loaded on 3% agarose gel and migrated for 30 minutes at 100 volts. All mice showed a control 
band of 289 bp while mice with the lox-p sites on one X chromosome displayed a band of 326 bp. 
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A wild type band around 179 bp representing the other X chromosome will appear only in female 
mice as male mice that carry the lox-p sites had no "normal" (P)RR gene (Figure 9). 
Figure 9: A gel image for the (P)RR loxP genotyping PCR. 
 
7.3 Body composition analysis  
Body composition was assessed via quantitative nuclear magnetic resonance spectroscopy (whole 
body composition analyzer; Echo medical system: EchoMRItm - 700) in live, conscious mice at 16 
weeks of age, before placing them in the physioscan cages. At the beginning of each measurement 
session, a system test was performed and the equipment was calibrated by scanning a calibration 
holder containing a known amount of fat to test the validity of the measurements. The instrument 
measures the body composition in terms of fat tissue, lean tissue, free water and total water.  
7.4 Locomotor activity  
Mice maintained on a normal diet were placed in sophisticated rodent cages (Physioscan from 
Accuscan) at 16 weeks of age to assess their locomotor activity. Body weight of each mouse was 
measured before inserting the animals one per cage. Mice had free access to food and water.  Data 
was collected over four nights and five days. Data for the first 3 days and 3 nights was omitted to 
allow mice to adapt to the new housing environment (Figure 10).  
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The system estimated the total horizontal distance traveled by each mouse every 2 minutes. A 
quantitative analysis of the total distance traveled was conducted with the data collected on the 
fourth day and fourth night. At the end of monitoring, mice were weighed and then returned back 
to their home cages and kept for one week for acclimatization. 
 
Figure 10: Physioscan cage 
 
7.5 Tissue collection 
At 22 weeks of age, animals were fasted overnight in clean cages with new bedding before tissue 
collection. Mice were sacrificed by CO2 asphyxiation. Blood was collected by heart puncture. 
Mouse body length was measured from the nose to the hip-joint. The different fat depots were 
collected, weighed and snap-frozen in liquid nitrogen and kept at -80oC for future analysis. This 
included the subcutaneous fat (SCF), perigonadal fat (PGF) and perirenal fat (PRF) as well as 
BAT. Tibias were also collected and their lengths were measured using a caliper.   
42 
 
 
In addition, many other tissues were excised such as aorta, diaphragm, pancreas, spleen, skeletal 
muscles, submandibular glands, gonads, heart, liver, brains, adrenals and kidneys. The weights of 
the later 5 tissues were monitored. Hearts were separated into their four chambers; each part was 
weighed and snap-frozen in liquid nitrogen. All other collected tissues were snap-frozen in liquid 
nitrogen and kept at -80o
7.6 Histology and adipose tissue cellularity 
C.  
 At sacrifice, parts of the PGF were fixed for 24 hours in 10% formalin at room temperature. 
Embedding, sectioning and staining were manipulated via the histology platform of the Research 
institute in Immunology and Cancer at the University of Montreal as follows: Each sample was 
paraffin-embedded. Adipose tissues were then cut with a microtome producing 4 μm sections. 
Images of the histological sections were obtained by light microscope fitted with a camera at 10x 
magnification lens. Image J software was used to detect the number and size of adipocytes in 3 
measurement frames (696×520 µm) for each section of adipose tissue (3 sections/mouse). For cell 
count, following actions were used: Plugins, analyze, cell counter. For cell area: manual tracing of 
each cell was done and then the area was calculated by the following actions: Analyze, measure. 
7.7  Real-time PCR for (P)RR expression  
Frozen tissues were grinded up into a fine powder using a stainless steel mortar and pestle which 
were kept frozen by being placed in liquid nitrogen. Total RNA was extracted from the tissue 
powders using 1 ml of TRIzol (Invitrogen, Burlington, ON, Canada). After adding chloroform and 
centrifugation at 4°C , an upper aqueous phase containing the RNA was separated from the middle 
interphase (DNA) and the lower red phase (Trizol, chloroform, protein and lipid), then transferred 
into new tubes. RNA was then precipitated using isopropranolol. The pellet was further washed in 
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75% ethanol and left to dry under a chemical hood. RNA was re-suspended in RNase free water 
according to pellet size and incubated for 10 minutes at 60°C and further quantified at 260/280 nm 
using a spectrophotometer. A modified protocol was used for adipose tissues in which an 
additional step is added to remove the lipid layer before the chloroform step.  
Extracted RNA was used to synthesize single-stranded cDNA. To remove genomic DNA, 1 µg 
RNA was incubated with a mix of 1U deoxyribonuclease I (DNase I; Invitrogen)/ug RNA , RNase 
free water and 10X DNase I reaction buffer for 15 minutes at room temperature. DNase reaction 
was inactivated by heating samples with 1 µl of 25 mM EDTA for 10 minutes at 65°C. A mix of 
random hexamer primers (200 ng/µl) and dNTP 10 mM was added and samples were heated for    
5 minutes at 65°C. Single-stranded cDNA was synthesized using SuperScriptII Reverse 
Transcriptase (Invitrogen) with the following program in a thermocycler: 10 minutes at 25°C 
followed by 50 minutes at 42°C and finishing with a 15 minutes at 70°C step.  
The real-time PCR final volume of 25 μl contained 0.3 µmol/l of the specific forward (F) and 
reverse (R) primers for (P)RR (F (5’TTTGGATGAACTTGGGAAGC-3’); R (5’-
CACAAGGGATGTGTCGAATG-3’)) or 18s (F ( 5' AAACGGCTACCACATCCAAG-3'); R ( 5'-
CCTCCAATGGATCCTCGTTA-3')) as well as 5 μl of 1:5 diluted single-stranded cDNA template 
in Quantitec SYBR Green PCR mix (Roche, Laval, QC, Canada) (1X final). Each sample was 
analyzed in duplicate. mRNA levels are expressed as values relative to 18s ribosomal RNA which 
was used as an internal control. 
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7.8 Plasma metabolites 
Collected blood samples were placed in 1.5 ml tubes containing 15 μl of EDTA 0.5 M pH 8.0, and 
spun down at 6000 g for 10 minutes at 4°C to recuperate plasma which was then frozen at -80°C 
until further assayed.  
Quantitative determination of glucose by enzymatic method using a commercially available kit 
(Wako) was done. The working solution was prepared by adding equal volumes of the reaction 
buffer and the color reagent.  For the standard curve, distilled water was used to prepare serial 
dilutions of the standard II solution. For the plasma, 2 µl of each sample were incubated with 200 
µl of the working solution for 5 minutes at 37o
The concentration of glucose (mg/dl) was calculated as follows: 
Glucose Concentratio(𝑚𝑔/𝑑𝑙) = 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 X Concentration of the standard 
C.  Each sample was done in duplicate. A FLUOstar 
OPTIMA spectrophotometer was used to read the absorbance of the plates at a wavelength of 505 
nm.  
Serum lipoprotein analyses were performed by High-Performance Liquid Chromatography 
(HPLC) with gel permeation columns (LipoSEARCH; Skylight-Biotec, Inc., Akita, Japan), which 
measured cholesterol and triglyceride levels in each lipoprotein fraction and lipoprotein particle 
size distribution simultaneously. Serum lipoproteins, triglycerides and cholesterol were analyzed 
by an HPLC system at Skylight Biotech (Akita, Japan) according to the procedures described by 
Usui et al 156, 157. Leptin and adiponectin were measured by ELISA kits at Morinaga Institute of 
Biological Science, Inc. (Kanagawa, Japan) and Otsuka Pharmaceuticals (Tokyo, Japan) 
respectively.  
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7.9 Proteinuria 
At 16 weeks of age, urine samples were collected manually in 1.5 ml tubes by restraining the mice 
mildly. Samples were kept at -80o
For albumin, serial dilutions of the standard were prepared using the diluent supplied with the kit 
as follows 10, 5, 2.5, 1.25, 0.625, 0.313, 0.156 μg/ml. A 1:20 dilution of the urine samples was 
prepared in the supplied diluent. Each sample was incubated for 30 minutes with the primary 
Rabbit Anti-murine Albumin Antibody. Plates were washed 10 times with water. Samples were 
further incubated for 30 minutes with 100 μl of Anti- rabbit HRP conjugate. Plates were washed 
again and samples were incubated for 10 minutes with 100 μl of the developer and then 100 μl of 
the color stopper were added. The absorbance for albumin was read at 490 nm.  
C for future analysis. Before measurement, each sample was 
thawed at room temperature. Albumin and creatinine urinary concentrations were measured in 
duplicate using the Albuwell and Creatinine companion mouse ELISA kits (Exocell, Philadelphia, 
PA).  
For creatinine measurement, a fresh picrate working solution was prepared by adding 2 ml of 1 N 
NaOH to a 10 ml bottle of picrate reagent. Urine samples were diluted 1:20 in distilled water. 
Serial dilutions of the creatinine standard were prepared as follow: 10, 3 and 1 mg/dl. 20 μl of the 
diluted samples were incubated for 10 minutes with 100 μl of working solution. Absorbance was 
read at 500 nm then samples were incubated with 100 μl of acid reagent for 5 minutes and 
absorbance was read again at 500 nm. Proteinuria was evaluated as the albumin/creatinine ratio. 
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7.10 Gene Affymetrix transcriptome 
For these experiments, total RNA was extracted from PGF of both males and females using 
TRIzol® reagent (Invitrogen, Carlsbad, CA) and purified with the RNeasy® MinElute cleanup kit 
(Qiagen, Valencia, CA) following the manufacturer’s recommendations. The quality of the total 
RNA was evaluated on an Agilent 2100 Bioanalyzer system (Agilent, Palo Alto, CA). Microarray 
experiments were performed using the GeneChip® Mouse Gene 1.0 ST array (interrogates 28 853 
genes), where each gene is represented by approximately 27 probes along the entire length of the 
transcript (Affymetrix, Santa Clara, CA). 100 ng of total RNA for each sample were processed 
using the Ambion® WT Expression Kit (Invitrogen). This kit uses a reverse transcription priming 
method that specifically primes non-ribosomal RNA, including both poly(A) and non-poly(A) 
mRNA, and generates at the end of the process sense-strand cDNA. 5.5 µg of the single-stranded 
cDNA were fragmented and labeled using the Affymetrix GeneChip® WT Terminal Labeling Kit 
and 2.0 µg of the resulting cDNA were hybridized onto the chip. The whole hybridization 
procedure was performed using the Affymetrix GeneChip® system according to the protocol 
recommended by Affymetrix. The hybridization was evaluated with Affymetrix GeneChip® 
Command Console Software (AGCC) and quality of the chips with Affymetrtix Expression 
Console. Partek Genomics Suite (Partek, St. Louis, Missouri) was used for data analysis. First, the 
data were normalized by Robust Multichip Average (RMA) algorithm, which uses background 
adjustment, quintile normalization and summarization. Then, the transcripts found to be 
significantly differentially expressed between WT and KO groups by more than 20% were 
included in the gene enrichment and pathway analyses, which were performed using web-based 
DAVID functional enrichment analysis, and Ingenuity Pathways Analysis (Ingenuity Systems, 
Inc., Redwood City, CA). Experiments were conducted at the CRCHUM genomic platform.  
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7.11 Statistical analysis 
 All values are expressed as mean ± standard error (SE). A repeated measures 2-way ANOVA was 
applied for weekly body weight, weight gain and food consumption. If any interactions were 
detected, a Tukey post-hoc test was used. A T-test was used for EchoMRI, physioscan and 
metabolic parameters as well as the (P)RR mRNA. A p ≤0.05 was considered statistically 
significant. 
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Chapter 8 : Results 
Knocking down of the receptor in white adipose tissues in both male and female mice was 
confirmed by comparing the levels of receptor expression in different white adipose tissue deposits 
and all other organs such as liver, kidneys, spleen, etc. A significant and specific decrease in the 
receptor expression was noticed in all white adipose tissue pads of KO males and females as 
compared to their WT littermates (Figure 11 and 12) and the level of expression was observed to 
be much lower in complete KO males as expected (Figure 11 and 12). No differences in the 
receptor expression were noticed in all other examined tissues (Figure 13 and 14). 
 
 
Figure 11: (P)RR expression in different adipose tissues of male mice.  
Male KO showed significantly lower levels of the (P)RR mRNA in their white adipose tissue pads 
as compared to their WT littermates while no changes could be detected in the brown adipose 
tissue. * p≤0.05, statistically different from WTs. N= 4 KOs and 4 WTs.  Brown adipose tissue, 
BAT; Subcutaneous fat, SCF; Perigonadal fat, PGF; Perirenal fat, PRF. 
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Figure 12: (P)RR expression in different adipose tissue pads of female mice.  
Female KO showed significantly lower levels of (P)RR mRNA in their white adipose tissue pads 
as compared to their WT littermates while, no changes could be detected in the brown adipose 
tissue. * p≤0.05, statistically different from WTs. N= 3 KOs and 3 WTs.  Brown adipose tissue, 
BAT; Subcutaneous fat, SCF; Perigonadal fat, PGF; Perirenal fat, PRF. 
 
 
Figure 13: (P)RR expression in different tissues of male mice.  
Male KO had no changes in the levels of (P)RR mRNA in the different organs assessed as 
compared to their WT littermates. N= 5 KOs and 5 WTs. Submandibular gland, SMG; Skeletal 
muscles; SM. 
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Figure 14: (P)RR expression in different organs of female mice. 
Female KO had no changes in the levels of (P)RR expression in their different organs as compared 
to their WT littermates. N= 3 KOs and 3 WTs. Submandibular gland, SMG; Skeletal muscles; SM. 
 
At 12 weeks of age, KO males presented with a significantly smaller body weights (28.3% less 
body weight) as compared to their WT littermates (22.2 ± 0.81 g versus 28.5 ± 0.98 g) (Figure 15). 
By following their weekly body weight and food intake for 4 weeks on normal diet, we determined 
that KO males maintained significantly smaller body weights as compared to their WTs (Figure 15 
and 16) but without any significant differences in their food intake when calculated as daily 
consumption in grams or as daily caloric consumption (Figure 17A and B). 
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Figure 15: Body weight of male mice.  
Male KO showed significantly lighter body weights over four weeks on normal diet as compared 
to their WT littermates. † p≤0.001, statistically different from WTs. N= 6 KOs and 10 WTs. 
 
  
Figure 16: Male mice.  
Pictures of complete KO male (on the left) and its WT littermate (on the right) at 16 weeks of age. 
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Figure 17: Food intake of male mice 
Over four weeks on normal diet, KO males showed no differences in their daily food consumption 
as expressed in grams (A) and in kilocalories (B) as compared to their WT littermates.  N= 6 KOs 
and 10 WTs. 
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By EchoMRI analysis of their body composition, KO males displayed a significant decrease in 
their fat mass in grams that was maintained when it was corrected for mice tibial length. However, 
they also had significant reduction in their lean body mass in grams (16% less lean mass) that was 
maintained when corrected for mice tibial length as compared to their WTs (Figure 18). Given that 
the male KO mice also had shorter tibial length (1.68 ± 0.03 versus 1.81 ± 0.02) this strongly 
suggests that these mice may have developmental issues potentially due to their extreme leanness.  
The decrease in fat mass observed by EchoMRI was confirmed by the significant reduction in 
PRF, SCF, PGF and BAT weights per se (Figure 19A) and corrected by tibial length (Figure 19B) 
as measured at sacrifice. In fact, KO males showed significantly lighter brain weights as compared 
to their wild type littermates even when it was corrected for tibial length (Table 2) while only a 
tendency for smaller heart weights could be observed which disappeared when heart weights were 
corrected for tibial length. Moreover, KO males tended to have smaller left ventricles (LV) which 
disappeared when corrected for mice tibial length (Table 3). They also showed no differences in 
the size of  any of the other heart chambers, even when corrected for tibial length, as compared to 
their WT littermates (Table 3). 
Interestingly, KO males showed significant increase in their locomotor activity as detected by the 
physioscan cages. KO males showed a 2-folds rise in the total horizontal distance traveled in both 
dark and light cycles as compared to their WT littermates (Figure 20). No obvious differences 
could be detected between the complete KO males and their WT littermates when looking at 
fasting glycemia (223 ± 20.49 versus 243 ± 32.03 mmol/l).  
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Figure 18: EchoMRI data analysis for male mice. 
Body composition analysis measured by EchoMRI demonstrated that KO males presented with not 
only a significant reduction in their total fat mass weight, but also  in their lean body mass as 
compared to their WT littermates (A). When corrected for the tibial length (B), these differences 
were maintained. Values are expressed as means ± SE.  * p≤0.05, statistically different from WTs. 
N= 4 KOs and 4 WTs.  
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Figure 19: Weights of different fat pads. 
Male KOs displayed significantly lighter white adipose tissue pads, weighed separately at sacrifice, 
in addition to lighter brown adipose tissue pads as compared to their WT littermates (A). These 
differences were maintained when values were corrected for tibial length (B). Values are expressed 
as means ± SE. * p≤0.05, statistically different from WTs. N= 6 KOs and 6 WTs . Brown adipose 
tissue, BAT; Subcutaneous fat, SCF; Perigonadal fat, PGF; Perirenal fat, PRF. 
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Table 2: Weights and lengths of different tissues in male mice 
 
 WT KO 
 Weight (g) Weight/tibia length ratio (g/cm) Weight (g) 
Weight/tibia length 
ratio (g/cm) 
Liver 1.118 ± 0.103 0.618 ± 0.060 1.022 ± 0.082 0.610 ± 0.053 
Heart 0.170 ± 0.023 0.091 ± 0.012 0.123 ± 0.007 0.073 ± 0.004 
Brain 0.471 ± 0.013 0.260 ± 0.007 0.355 ± 0.015† 0.215 ± 0.009‡ 
kidneys 0.384 ± 0.029 0.156 ± 0.029 0.343 ± 0.020 0.187 ± 0.020 
Adrenal 0.010 ± 0.004 0.006 ± 0.002 0.008 ± 0.001 0.005 ± 0.001 
Values are expressed as means ± SE. † p≤0.001, ‡ p≤0.005 statistically different from WTs. N= 6 
KOs and 6 WTs. Whole organs were weighed separately at sacrifice. Red color: KO males showed 
significantly lighter brain weights as compared to their wild type littermates even when it was 
corrected to tibial length. 
 
Table 3: Weights of different heart chambers in male mice 
 
 WT KO 
 Weight (g) Weight/tibia length ratio (g/cm) Weight (g) 
Weight/tibia length 
ratio (g/cm) 
Left ventricle 0.087 ± 0.006 0.049 ± 0.004 0.081 ± 0.007 0.050 ± 0.005 
Left atrium 0.012 ± 0.003 0.007 ± 0.002 0.003 ± 0.000 0.002 ± 0.000 
Right ventricle 0.021 ± 0.001 0.012 ± 0.001 0.022 ± 0.005 0.013 ± 0.003 
Right atria 0.007 ± 0.004 0.004 ± 0.002 0.007 ± 0.002 0.004 ± 0.002 
Values are expressed as means ± SE. N= 3 KOs and 3 WTs. Heart chambers were separated and 
weighed at sacrifice.  
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Figure 20: Locomotor activity of male mice. 
KO males traveled significantly longer total distances in physioscan cages during both dark and 
light cycle as compared to their WT littermates. † p≤0.001, * p≤0.05 statistically different from 
WTs. N= 4 KOs and 6 WTs.  
 
As expected, female partial KO mice presented with similar phenotypes then the males but with 
less pronounced differences in comparison to their WT littermates. As such, partial KO females 
had initially significant lighter body weights (10.9% less body weight)  which was maintained 
throughout the four weeks of measurement while they were on a normal diet (14% less body 
weight) (Figure 21).  Interestingly, when a group of these mice was transferred to a HF/HC diet, 
they showed significant resistance to weight gain and had significantly lighter body weights over 
the 6 weeks of administration (Figure 22A, B and Figure 23).  Moreover, similarly to what was 
observed in male mice, no significant differences in food intake could be detected when calculated 
as daily consumption in grams or as daily caloric consumption on either the normal diet or the 
HF/HC diet (Figures 24 and 25).  
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Figure 21: Body weight of female mice on normal diet. 
Female KO mice showed significantly lighter body weights over four weeks on a normal diet as 
compared to their WT littermates. Values are expressed as means ± SE.  † p≤0.001, statistically 
different from WTs. N= 11 KOs and 11 WTs. 
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Figure 22: Body weight and weight gain of female mice on HF/HC diet. 
Female KO mice showed significantly lighter body weights when kept for six weeks on HF/HC 
diet (A), and as such, they were significantly resistant to weight gain (B). Values are expressed as 
means ± SE.  † p≤0.001, ∗ p≤0.05, statistically different from WTs. N= 7 KOs and 8 WTs. 
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Figure 23: Female mice on HF/HC diet:  
Pictures of partial KO female (on the left) and its WT littermate (on the right) at 22 weeks of age. 
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Figure 24: Food intake of female mice on normal diet. 
Over four weeks on normal diet, female KO mice showed no differences in their daily food 
consumption as expressed in grams (A) and in kilocalories (B) as compared to their WT 
littermates.  Values are expressed as means ± SE.  N= 11 KOs and 11 WTs. 
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Figure 25: Food intake of female mice on HF/HC diet. 
Over six weeks on a HF/HC diet, female KO showed no differences in their daily food 
consumption as expressed in grams (A) and in kilocalories (B) as compared to their WT 
littermates. Values are expressed as means ± SE.  N= 7 KOs and 8 WTs. 
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Also, as determined in the male mice, EchoMRI analysis of the body composition for the partial 
KO females on the normal diet demonstrated that they had significantly less fat and lean body 
mass in grams (Figure 26A) that was maintained when corrected for mice tibial length (Figure 
26B). Similarly to what was observed on the normal diet, the group of females that was transferred 
to the HF/HC diet showed significantly less fat mass in grams as compared to their WT littermates 
but without detectable differences in mice lean body mass (Figure 27A) even when corrected to 
mice tibial length (Figure 27B). The EchoMRI observations were associated with a significant 
reduction in subcutaneous and perigonadal fat in addition to a strong tendency for less perirenal fat 
on both normal and HF/HC diet (Figures 28A and 29A) even when corrected to mice tibial length 
(Figures 28B and 29B).   
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Figure 26: EchoMRI analysis for female mice on normal diet. 
After 4 weeks on a normal diet, body composition evaluated by EchoMRI demonstrated that 
female KO showed not only significantly lower fat mass weight but also less lean body mass as 
compared to their WT littermates (A).These differences were also maintained when values were 
corrected for tibial length (B). Values are expressed as means ± SE. † p≤0.001, * p≤0.05, 
statistically different from WTs. N= 11 KOs and 11 WTs.  
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Figure 27: EchoMRI analysis for female mice on HF/HC diet. 
When female KO were placed on a HF/HC diet, evaluation of the body composition by EchoMRI 
demonstrated that they had significantly less fat mass but without any significant differences in 
their lean body mass as compared to their WT littermates (A). These differences were maintained 
when values were corrected for tibial length. Values are expressed as means ± SE. ‡p≤0.005, * 
p≤0.05 statistically different from WTs. N= 7 KOs and 7 WTs.  
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Figure 28: Weights of different fat pads for female mice on normal diet. 
After 4 weeks on a normal diet, female KO showed significantly lighter subcutaneous (SCF) and 
perigonadal (PGF) fat , weighed separately at sacrifice, as compared to their WT littermates 
(white) while perirenal (PRF) and brown adipose tissue (BAT) pads only tended to be lighter (A). 
These differences were maintained when the weights of these tissues were corrected for tibial 
length (B). Values are expressed as means ± SE. * p≤0.05, statistically different from WTs. N= 11 
KOs and 11 WTs. 
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Figure 29: Weights of different fat pads for female mice on HF/HC diet. 
After 4 weeks on a HF/HC diet, female KO showed significantly lighter subcutaneous (SCF) and 
perigonadal (PGF) fat, weighed separately at sacrifice, as compared to their WT littermates (white) 
while perirenal (PRF) and brown adipose tissue (BAT) pads only tended to be lighter (A). These 
differences were maintained when the weights of these tissues were corrected for tibial length (B). 
Values are expressed as means ± SE.  * p≤0.05, statistically different from WTs. N= 6 KOs and 6 
WTs. 
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In addition, partial KO females on the normal diet showed no diffrences in tibial lengths as 
compared to their WT littermates (1.793 ± 0.017 versus 1.759 ± 0.018 cm). They also tended to 
have  a lighter brain and heart weights compared to the WT mice with no differences in liver and 
kidney weights (Table 4) but these tendencies disappeared when the weights were corrected for the 
tibial length (Table 4). Moreover, partial KO females tended to have smaller right ventricles (RV) 
even when corrected for tibial length (Table 5) and also tended to have smaller left ventricles (LV) 
which disappeared when corrected for mice tibial length (Table 5). They also showed no 
differences in the size of  the left and right atria (LA and RA) even when corrected for tibial length 
as compared to their WT littermates (Table 5). 
On the other hand, KO females that were placed on a HF/HC diet tended to have lighter liver 
weights as compared to their WT littermates that were maintained when corrected for tibial length 
without any differences in heart and kidney weights (Table 6).  
As in males, no obvious differences in glycemia were detected between partial KO females and 
their WT littermates either on the normal diet (207 ± 29.09 versus 163 ± 30.17 mmol/l) or on the 
HF/HC diet (144±20.99 versus 130±19.60 mmol/l). 
Interestingly, KO females on the normal diet tended to have less proteinuria as estimated by 
albumin/creatinine ratio compared to their WT littermates (0.10 ± 0.01 versus 0.23 ± 0.06 μg/mg). 
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Table 4: Weights and lengths of different tissues in female mice on normal diet 
 
 WT KO 
 Weight (g) Weight/tibia length ratio (g/cm) Weight (g) 
Weight/tibia length 
ratio (g/cm) 
Liver 1.118 ± 0.063 0.623 ± 0.033 1.002 ± 0.053 0.569 ± 0.028 
Heart 0.130 ± 0.007 0.072 ± 0.003 0.111 ± 0.011 0.063 ± 0.006 
Brain 0.476 ± 0.007 0.010 ±0.003 0.445 ± 0.017 0.253 ± 0.010 
kidneys 0.147 ± 0.004 0.082 ±0.002 0.144 ± 0.005 0.082 ± 0.002 
Adrenal 0.012 ± 0.003 0.007 ±0.002 0.010 ± 0.002 0.006 ± 0.001 
Values are expressed as means ± SE. N= 11 KOs and 11WTs. Whole organs weighed at sacrifice 
 
Table 5: Weights of different heart chambers in female mice on normal diet. 
 
 WT KO 
 Weight (g) Weight/tibia length ratio (g/cm) Weight (g) 
Weight/tibia length 
ratio (g/cm) 
Left ventricle 0.089 ± 0.004 0.050 ± 0.002 0.085 ± 0.004 0.049 ± 0.002 
Left atrium 0.003 ± 0.0005 0.001 ± 0.000 0.003 ± 0.0005 0.001 ± 0.000 
Right ventricle 0.024 ± 0.002 0.013 ± 0.001 0.017 ± 0.003 0.010 ± 0.002 
Right atrium 0.004 ± 0.001 0.002 ± 0.001 0.006 ± 0.001 0.003 ± 0.001 
Values are expressed as means ± SE. N= 8 KOs and 8 WTs. Heart chambers were separated and 
weighed at sacrifice.  
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Table 6: Weights and lengths of different tissues in female mice on HF/HC diet. 
 
 WT KO 
 Weight (g) Weight/tibia length ratio (g/cm) Weight (g) 
Weight/tibia length 
ratio (g/cm) 
Liver 1.211 ± 0.058 0.664 ± 0.031 1.031 ± 0.073 0.562 ± 0.041 
Heart 0.149 ± 0.005 0.082 ± 0.004 0.147 ± 0.006 0.080 ± 0.003 
kidneys 0.333 ± 0.010 0.182 ± 0.007 0.343 ± 0.013 0.187 ± 0.007 
Values are expressed as means ± SE. N= 6 KOs and 6 WTs. Whole organs were weighed at 
sacrifice.  
However, in contrast to the male KOs, no significant differences could be observed in the 
locomotor activity of female KOs as compared to their WTs (Figure 30). 
In accordance with their decreased weight gain with the administration of a HF/HC diet, partial 
KO females strongly tended to have less plasma leptin levels (Figure 31) while no detectable 
differences of adiponectin levels (32.2 ± 4.97 versus 32.5 ± 3.59). In addition, no differences in 
fasting plasma total cholesterol levels (87.643 ± 18.706 versus 87.428 ± 12.563 mg/dl) or fasting 
plasma total triglyceride levels (41.695 ± 8.917 versus 38.395 ± 7.697 mg/dl) were detected 
between female KOs and WTs.   
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Figure 30: Locomotor activity of female mice. 
Partial KO females on normal diet didn’t show significant differences in their total distance 
traveled at physioscan cages during both dark as well as light cycle as compared to their WT 
littermates. N= 7 KOs and 7 WTs. 
 
 
 
Figure 31: Plasma leptin level of female mice on HF/HC diet. 
Partial KO females on HF/HC diet tended to have less plasma leptin levels  compared to their WT 
littermates. Values are expressed as means ± SE. N= 6 KOs and 6 WTs. 
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The histological analysis of the perigonadal fat pads of female mice on a normal diet revealed a 
significant increase in the average size of adipocytes accompanied by a significant decrease in 
adipocyte number (Figure 32). 
The Gene Affymetrix transcriptome of the perigonadal fat of male and female KOs mice 
demonstrated an associated change in the regulation of different genes as shown in Table 7. Of 
note, one of the genes which was found to be down regulated is the Mutant human ABLIM2 gene 
(SNP substitution mutation, allelic variations: A/G (rs1574131)) which has been found to be 
associated with non-insulin-dependent diabetes mellitus (Table 7). 
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A) 
        
B)                                                                           C) 
   
 
Figure 32: White adipose tissue histology. 
(A) Stained sections (hematoxylin and eosin) of perigonadal fat of female KO (left) and WT (right) 
mice on normal diet. Scale bar: 100 µm. (B) female KO on a normal diet displayed a significantly 
less number of adipocytes in their perigonadal fat associated with signifcantly larger adipocytes 
(C) as compares to their WT littermates. Values are expressed as means ± SE. † p≤0.001, * p≤0.05 
N= 4 KOs and 4 WTs.   
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Chapter 9 : Discussion 
To our knowledge, we are the first group to knock down the (P)RR in white adipose tissue. We 
validated our model by evaluating the (P)RR mRNA expression in many organs, comparing KO 
mice to their WT littermates. We found a unique and tissue specific decrease in the receptor 
expression level in white adipose tissue pads (subcutaneous, perirenal and perigonadal fat) in the 
KO mice while no differences could be detected in all other evaluated tissues. The percentage of 
the deletion of the receptor gene was around 50% in the white adipose tissue of the complete KO 
males and around 30% in those of the partial KO females.  However, in these experiments, we 
examined whole adipose tissue fat pads which are a mix of adipocytes and other cells such as 
fibroblasts, endothelial cells, preadipocytes, and macrophages as well as many small blood vessels. 
In this type of experiment around 70-80% deletion has been often observed with other genes using 
the AP2 promoter 158. However, since adipocytes compose approximately 50% of the cells in 
adipose tissue90 and that the (P)RR is known to be quite ubiquitous34
As expected, we noticed a more accentuated phenotype in male KO mice compared to females 
since the (P)RR gene is carried on the X chromosome 
  it is not that surprising that 
we observed lesser levels of gene expression deletion. As such, we anticipate that this deletion 
probably targeted adipocytes specifically although to verify this, adipocyte isolation will be 
required.   
41. Indeed, because of our breeding strategy, 
male mice were complete KOs whereas females were only partial KO. We have noticed that we 
seemed to have a reduced number of male KO mice per litter as determined after weaning than 
what would be expected by the Mendelian genetics. This suggests that there are some lethality 
occurred as a result of complete knocking down of the receptor in adipose tissue.  
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In fact, a similar but more sever shortening of mice life span was shown when (P)RR was knocked 
down uniquely in other cell types such as cardiomyocytes as well as podocytes 40, 61
As expected, female partial KO mice had similar but less pronounced phenotypes than that of the 
males regarding the body weight and composition changes as well as food intake on a normal diet 
and these phenotypes were accentuated when the females were transferred to HF/HC diet although 
no detectable changes could be measured for their locomotor activity. However, female KO mice 
had no significant changes in their tibial length. 
. In addition, 
we were able to determine which males were KOs directly in the cage because of their much lower 
body weights. Furthermore, complete KO males presented with a 28% lighter body weights at 16 
weeks of age when maintained on a normal diet which was not associated with any changes in 
daily caloric food intake. These weight changes were characterized by a significant reduction in fat 
mass. However, a significant reduction in their lean body mass was also detected. Given that they 
also showed significantly shorter tibias, this strongly suggests that these mice may have 
developmental issues as a result of the adipose tissue (P)RR deletion or because of the extreme 
leanness of these animals. However, given that female KO mice also exhibited a decrease in lean 
body mass with a less pronounced decrease in fat mass, this suggests that specific deletion of the 
(P)RR in adipose tissue may contribute to maturation potentially through the modulation of 
different adipokines.    
Ang II was reported to have a lipogenic effect as it enhances adipocytes accumulation of 
triglycerides126 and stimulates the activity of lipogenic enzymes146 which contributes to expanding 
the adipose tissue mass. As mentioned earlier in the text, activation of the (P)RR leads to an  
increase in renin’s catalytic efficiency and to a non-proteolytic activation of prorenin 34. As such, it 
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may contribute to an increase in the local production of Ang II which could further expand the 
white adipose tissue mass.  
Therefore, one of the underlying mechanisms for the phenotype observed in our KO mice could be 
through decreasing the renin and prorenin activity which would produce a decrease in Ang II-
dependent effects on white adipose tissues and decrease its growth.  
It was reported that complete knocking down of the AT1Ra in their adipocytes showed no changes 
in their body weight and fat mass but displayed a significant adipocytes hypertrophy as a result of 
a decrease in adipocyte differentiation. Authors suggest that the increase in expression of other 
RAS receptors (AT1Rb and AT2R) may have compensated for the decrease of AT1Ra which may 
have contributed to a less striking phenotype 158
As such, the (P)RR may impact adipose tissue mass  through its Ang II-independent pathways, for 
instance, by producing MAPK activation and thus releasing TGF-ß1and profibrotic molecules such 
as, PAI-1, fibronectin protein and collagen I. On the other hand, it can also phosphorylate and 
. However, our partial KO female mice had 
significantly lower body weights in association with a decrease in fat mass on normal diet and 
were resistant to body weight gain on HF/HC diet.  In addition, their perigonadal fat showed 
similar histological phenotype on normal diet in the form of marked increase in adipocytes size in 
association with decrease of the adipocytes number. This suggests that RAS mechanisms are 
involved but that additional Ang II-independent pathways may enhance this phenotype so that a 
marked decrease in fat mass is observed. It will be important however to establish if compensatory 
mechanisms involving an increase in the expression of other RAS components in adipose tissue 
may mask the extent of the impact of the (P)RR deletion as what was observed in mice lacking 
AT1Ra. It will be also interesting to examine the differentiation capacity of preadipocytes to 
identify the potential mechanisms implicated in this histological phenotype.  
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activate p38 MAPK as well as the HSP27. Through these factors, the (P)RR is thought to play a 
role in regulating the cell integrity, growth, motility and apoptosis. Therefore, these pathways 
could be implicated in the decreased white adipose tissue mass observed in the KO mice.  
In addition, the functional (P)RR/V-ATPase relation could be implicated in the histological 
changes noticed for KO mice. As mentioned earlier in the text, the principle roles of V-ATPases 
are the acidification of intracellular compartments and proton pumping in different cell types. As 
such, it was found that deletion of (P)RR specifically in cardiomyocytes as well as in podocytes 
resulted in lethal histological abnormalities in these cell types later in life in association with the 
disruption of the V0 domain of V-ATPase. Hence, given the similar phenotype that is observed in 
adipocytes following the deletion of the (P)RR, evaluating the different domains of V-ATPase in 
adipocytes will be an important continuation for this study. Furthermore, the potential 
developmental issues observed in the KO mice could be as a result of the interaction with the V-
ATPase. In fact, it was found that deletion of the receptor ubiquitously in Zebra fish is lethal and 
was associated with developmental abnormalities, which means that the (P)RR gene is essential for 
embryonic development 41. As mentioned earlier in the text, the (P)RR was found to be implicated 
in the Wnt/β-catenin signaling pathway via its interaction with the V-ATPase 55. Since the Wnt 
proteins have been shown to be essential for normal embryogenesis 54
 
, it may be suggested that the 
complete deletion of the (P)RR lead to dysregulation of Wnt signaling, resulting in developmental 
malformation in KO mice. However, other experiments will be needed to determine the exact 
mechanism implicated in the developmental issues, such as by investigating the proteins of Wnt/β-
catenin signaling in the adipocytes.  
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An important factor that could also contribute to the decrease in fat mass observed in our male and 
female KO mice is the possible increase in energy expenditure.  
We would expect energy expenditure to be increased in our KO mouse model due to a rise in lipid 
oxidation given the reported effect of increased RAS activity in adipose tissue. Furthermore, 
although we did not evaluate this parameter in the current study, the increased locomotor activity 
observed in the male mice strongly suggests that they also have an increase in their daily energy 
expenditure. Although it is hard to determine the exact mechanism for this effect, similar findings 
have also been found in mice lacking AGT in their adipose tissue 141
We have previously shown in our laboratory that using the (P)RR blocker systemically improved 
the metabolic profile in mice treated with a HF/HC diet. However, we were unable to see these 
improvements in the current study although female mice were not treated with the HF/HC diet for 
a prolonged period of time as what had been done previously. Moreover, it is possible that 
systemic administration of the (P)RR blocker may have affected other organs such as the pancreas, 
which may have also contributed to the improvement of the metabolic profile. We have however 
noticed a down regulation of the ABLIM2 gene which was found to be associated with the 
development of type II diabetes in humans 
. This thus suggests that 
adipose tissue RAS may have remote effects on the central nervous system. In fact, sympathetic 
activity was previously found to be increased when evaluated in AT1Ra null mice although 
unfortunately, locomotor activity was not evaluated in this study. So, overstimulation of the 
sympathetic activity could be a potential mechanism. Assessment of sympathetic activity as well as 
thermogenesis via the measurement of urinary catecholamines, mice body temperature as well as 
the expression and protein level of the UCP-1 gene in collected brown adipose tissues are to be 
done in the future. 
159. Additional experiments will be needed to further 
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investigate the regulation of glycemia and insulinemia through the oral glucose tolerance tests 
(OGTT) or intra-peritoneal insulin tolerance test (IPITT).  
Moreover, when female KO mice were placed on a HF/HC diet, they tended to show lighter liver 
weights. This may suggest that they accumulated less fat in their livers. If this is the case, it 
suggests that KO females probably will be less susceptible to develop non-alcoholic fatty liver 
disease (NAFLD). NAFLD is excess accumulation of triglycerides and fats in adipocytes so that it 
exceeds %5 of the liver weight and it is a part of the metabolic changes that accompanies the 
development of obesity and could lead to metabolic disorders such as hepatic insulin resistance160, 
161
In conclusion, KO males and females showed lighter body weights on normal diet in association 
with decreased fat and lean body mass.  The KOs gonadal fat showed reduced adipocyte numbers 
of bigger size and reduced expression of ABLIM2 gene that is associated with human diabetes. In 
addition, the KO females were resistant to obesity development when placed on a HF/HC diet and 
thus showed less fat mass. Male KOs seemed to have developmental abnormalities as they 
presented with shorter tibial length. Moreover, we observed marked increase in locomotor activity 
in male KOs which may have contributed to their decreased fat mass and total body weight.  
.  
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Chapter 10 : Conclusion and perspectives 
The current study shows the implication of the (P)RR in the development of obesity through a 
mouse model that lacks the receptor in white adipocytes. As the (P)RR gene is located on the X- 
chromosome, we had homozygote complete knock-out males while heterozygote partial knocked 
out females. Males and females’ whole white adipose tissue pads showed 50% and 30% reduction 
in the receptor expression respectively. Thus, given that the adipose tissue is constituted of many 
different cell types, looking at the receptor expression in isolated adipocytes will be needed for a 
better validation of the model. KO males and females showed lighter body weights on normal diet 
with decreased fat and lean body mass although no changes in the food intake could be observed. 
We used the Cre/loxp recombination technology and thus produced the KO in the fetus; however, 
it will be interesting to use this technology to induce the knock down the receptor in adult mice to 
avoid possible compensating mechanisms that might occur during mice development. As such, this 
may allow a better evaluation of the phenotype related specifically to a deficiency in the (P)RR. It 
would be interesting to investigate if knocking down the receptor might have decreased the 
intestinal fat absorption similarly to what has been observed mice lacking the renin gene 129
On the other hand, the gonadal fat showed reduced adipocytes number of bigger size. Since these 
histological results are more pronounced than what have been reported in mouse KOs of other 
RAS members in white adipose tissue, we suspect that Ang II-independent pathways of the (P)RR 
are also implicated in these changes. Thus assessment of both adipocytes Ang II-dependent and -
independent pathways would be needed to verify the underlying mechanisms of the reported 
phenotypes. As such, it would be of interesting to measure renin activity, Ang II levels as well as 
the total and phosphorylated ERK1/2 in adipocytes. In addition, female KOs were resistant to the 
. This 
might indeed contribute to the weight change observed in these animals.  
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development of obesity when placed on a HF/HC diet however this treatment has not yet been 
assessed in male KOs. Hence, evaluating the effect of a HF/HC diet in male KOs will be required 
and it will be interesting to see if lean body mass is still decreased in these animals as we observed 
a normalization of the lean body mass weight with the administration of the HF/HC diet to the 
females.   
Also, as mentioned earlier, marked increases in locomotor activity was observed in male KOs 
which could also be implicated in the smaller body weights of these mice. Moreover, sympathetic 
activity has been reported to be increased in AT1Ra null mice and so, investigating the 
sympathetic activity in the male KOs could be suggested as one of the possible implicated 
mechanism for the increased locomotor activity. As type II diabetes is a common complication of 
obesity, we assessed the fasting glycemia in these mice although no obvious change could be 
observed. However, we did measure a reduced expression of the ABLIM2 gene that is associated 
with human diabetes in gonadal fats of KOs. Thus a more sensitive evaluation of the glycemia 
would be needed either by the oral glucose tolerance tests (OGTT) or intra-peritoneal insulin 
tolerance test (IPITT) in order to evaluate this parameter more closely. Moreover, evaluating 
glucose homeostasis in mice which have been placed on a HF/HC diet may be required to better 
distinguish the differences produced by the (P)RR deficiency.  
Although no detectable differences in lipid profile could be observed in female mice on a HF/HC 
diet, given their mild phenotype, we may not have sufficient accuracy to detect small changes. As 
such, it would be of interest to investigate this parameter in the males since they have a more 
pronounced phenotype. In fact, studies have reported an association between the metabolic 
syndrome and the increased albumin in urine 162, 163. In addition, obesity is a great risk factor for 
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developing hypertension and type II diabetes and thus it is considered as an important risk factor 
for the chronic kidney diseases 164
Based on the data that we obtained from partial knocking down of the (P)RR, we would expect that 
the receptor could potentially be a new regulator of the adipose tissue mass and body weight. We 
have recently demonstrated in our laboratory that systemic administration of a (P)RR blocker in 
obese mice resulted in a decrease in weight gain and normalization of glycemia and triglycerides 
as well as a reduction in insulinemia. In addition, it prevented the fall in cardiac functions observed 
with increased obesity 
. Thus, looking at the proteinuria in mice on HF/HC diet will be 
important to see if the KOs are more prone to develop proteinuria with obesity or not. 
154
 
. Taken together, the (P)RR and its blocker seem to be a new therapeutic 
target in the prevention of obesity and its associated metabolic disorders.  
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